Zacks Small Cap Research on MSN2d
LEXX: IRB Approval Clears Way for GLP-1 Study #5
LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...
Healthcare Dive13d
Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.
Novo sells semaglutide as Ozempic, Rybelsus and Wegovy. The CMS will treat the different forms as a single product in price ...
Healio1d
Increase in online searches for obesity drugs correlates with rise in prescriptions
The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...
Morningstar16d
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
Furthermore, the oral DehydraTECH-tirzepatide evidenced a comparable ... the only GLP-1 drug available today both in an oral form (Rybelsus®) and as an injectable (Ozempic® and Wegovy ...
New York Post23d
Ozempic 3.0? This drug causes the greatest weight loss — by far
Tirzepatide, a weekly GLP-1 and GIP drug ... The FDA approved Novo Nordisk’s semaglutide tablet Rybelsus for adults with diabetes but not for weight management. Mild gastrointestinal issues ...
T-Net9d
Lexaria Says Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound
Lexaria Bioscience Corp., a global innovator in drug delivery platforms, has announced partial final results showcasing the ...